Posted on Friday, April 23, 2010
Here is some pretty interesting news from Clarient:
Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that data from a new study suggest that the Clarient Insight® Dx Pulmotax™ assay may effectively predict which lung cancer patients will respond favorably to chemotherapy. The study, titled “TLE3 expression is predictive of response to chemotherapy in NSCLC,” included 368 samples from carcinoma patients. The majority of advanced-stage patients who were treated with chemotherapy received a treatment regimen containing a taxane class agent.
Pulmotax is a single antibody immunohistochemistry test created to detect the expression of TLE3 in non-small cell lung cancer (NSCLC). Prior data have linked TLE3 expression specifically to response to taxane therapy in breast and ovarian carcinoma patients. The study was presented yesterday at the annual meeting of the American Association of Cancer Research (AACR) in Washington, D.C. by Douglas T. Ross, M.D., Ph.D., Chief Scientific Officer of Clarient.
The study summary and results may be found at http://www.clarientinc.com/Pulmotax.